Brief: Acura's Limitx technology successfully confirms oral abuse deterrence capabilities
08/06/2016 21:17
June 8 (Reuters) - Acura Pharmaceuticals Inc:
* Acura Pharmaceutical's Limitx(tm) technology successfully
confirms oral abuse deterrence capabilities
* Company expects to resume clinical testing of a new
formulation of LTX-04 in Q4 of 2016
Source text for Eikon: ID:nMKW2RtS7a
((Bengaluru Newsroom: +1-646-223-8780))
Recent news on Acura Pharmaceuticals
See all newsBrief: Acura Pharmaceuticals Received A $250,000 Loan From Abuse Deterrent Pharma, LLC on October 11
Brief: Acura Pharmaceuticals Inc Receives $200,000 Loan From Abuse Deterrent Pharma
Brief: Acura Pharmaceuticals Received $250,000 Loan From AD Pharma For Operations Through End Of April 2023
Brief: Acura Pharmaceuticals, AD Pharma Amend License to LIMITx LTX-03
Insight: Novavax bosses cash out for $46 mln with COVID-19 vaccine trials still under way